Edarby Cloe
Edarby Clos: instructions for use and reviews
- 1. Release form and composition
- 2. Pharmacological properties
- 3. Indications for use
- 4. Contraindications
- 5. Method of application and dosage
- 6. Side effects
- 7. Overdose
- 8. Special instructions
- 9. Application during pregnancy and lactation
- 10. Use in childhood
- 11. In case of impaired renal function
- 12. For violations of liver function
- 13. Use in the elderly
- 14. Drug interactions
- 15. Analogs
- 16. Terms and conditions of storage
- 17. Terms of dispensing from pharmacies
- 18. Reviews
- 19. Price in pharmacies
Latin name: Edarbi Klo
ATX code: C09DA09
Active ingredient: azilsartan medoxomil + chlortalidone (azilsartan medoxomil + chlortalidone)
Manufacturer: Takeda Pharmaceutical Company (Japan)
Description and photo update: 2018-27-07
Prices in pharmacies: from 664 rubles.
Buy
Edarbi Clos is a combined antihypertensive agent.
Release form and composition
Edarbi Clo is produced in the form of film-coated tablets: biconvex, round; pale pink with the inscriptions "D / S" and "40 / 12.5" applied on one side in gray ink - dosage 40 mg + 12.5 mg, or gray-pink with inscriptions in gray ink "D / S" and "40/25" - dosage 40 mg + 25 mg (14 pieces in an aluminum blister, 2 blisters in a cardboard box; 7 pieces in an aluminum blister, 4 blisters in a cardboard box).
1 film-coated tablet contains:
- active substances: azilsartan medoxomil potassium - 42.68 mg (corresponds to azilsartan medoxomil in the amount of 40 mg), chlorthalidone - 12.5 or 25 mg;
- additional components: sodium hydroxide, mannitol, fumaric acid, microcrystalline cellulose, crospovidone, hyprolose, magnesium stearate;
- film shell: titanium dioxide, hypromellose 2910, macrogol 8000, iron dye red oxide, talc, F1 gray ink purified for marking (contains iron dye black oxide, ethanol, butyl alcohol, shellac).
Pharmacological properties
Pharmacodynamics
Edarbi Clo is a combined antihypertensive drug, which includes an angiotensin II receptor antagonist (ARA II) - azilsartan medoxomil, and a thiazide-like diuretic - chlorthalidone. The combined use of these active substances provides a more pronounced decrease in blood pressure (BP) when compared with taking each of them as a monotherapy drug. Taking Edarbi Clos 1 time per day leads to an effective decrease in blood pressure for 24 hours.
Azilsartan medoxomil belongs to the specific ARA type II (AT 1). Angiotensin II is formed from angiotensin I in a reaction catalyzed by an angiotensin-converting enzyme (ACE, kininase II). Angiotensin II is the main vasoconstrictor factor of the renin-angiotensin-aldosterone system (RAAS), its effect is vasoconstriction, stimulation of aldosterone production, increased heart rate (HR) and sodium reabsorption by the kidneys.
Azilsartan medoxomil is an oral prodrug. The substance is rapidly transformed into an active molecule of azilsartan, which selectively blocks the development of the effects of angiotensin II by inhibiting the connection of the latter with the AT 1 receptor in various tissues, including in the adrenal glands and smooth muscles of the vascular walls. As a result, its effect is not associated with the course of biosynthesis of angiotensin II. The AT 2 receptor is localized in many tissues, but does not affect the regulation of the cardiovascular system (CVS). The affinity of azilsartan for the AT 1 receptor is 10,000 higher than that for the AT 2 receptor.
In the treatment of arterial hypertension, ACE inhibitors, which suppress the formation of angiotensin II from angiotensin I, and thereby inhibit the activity of the RAAS, have been widely used. ACE inhibitors also block the breakdown of bradykinin, which is catalyzed by ACE; since azilsartan does not inhibit kininase II, its effect should not extend to the action of bradykinin. The substance also does not affect other receptors or ion channels, which are of great importance in the regulation of CVS.
Azilsartan dose-dependently inhibits the vasoconstrictor effect during infusion of angiotensin II. A single dose of azilsartan in an amount corresponding to 32 mg of azilsartan medoxomil inhibited the maximum vasoconstrictor effect of angiotensin II at the time of the highest concentration by about 90%, and by about 60% - 24 hours after administration. After a single oral dose and after repeated doses of azilsartan medoxomil, healthy volunteers showed an increase in the concentration of angiotensin I and II and renin activity in plasma, as well as a decrease in the level of aldosterone. At the same time, no significant changes in serum potassium or sodium levels in the blood were detected. The pharmacodynamic properties of azilsartan medoxomil are generally combined with the suppression of AT 1 receptors.
The development of the antihypertensive effect of this substance occurs during the first 2 weeks of the course, and the maximum therapeutic effect is noted after 4 weeks. After oral administration of a single dose, a decrease in blood pressure is achieved, as a rule, within a few hours and persists for 24 hours.
Chlorthalidone is a thiazide-like diuretic that inhibits the active reabsorption of sodium ions in the renal tubules (in the initial part of the distal convoluted tubule of the nephron). As a result of this, the active substance increases the excretion of chlorine and sodium ions and enhances diuresis, it also helps to enhance the excretion of magnesium, potassium, bicarbonate ions, retains uric acid and calcium ions.
The antihypertensive properties of the drug are due to the excretion of sodium and fluid from the body. The diuretic effect is observed 2-3 hours after oral administration of chlorthalidone and lasts for 2-3 days. The antihypertensive effect manifests itself gradually and reaches its maximum effect 2–4 weeks after the start of treatment.
In clinical trials, the combined use of azilsartan medoxomil and chlorthalidone was more effective than the combination of azilsartan medoxomil or olmesartan medoxomil with hydrochlorothiazide, despite the fact that more study participants in the comparison group needed an increase in dose due to insufficient blood pressure control. In a double-blind study, during which the dose was routinely increased for 12 weeks, the combined use of azilsartan medoxomil and chlorthalidone (40 and 25 mg, respectively) significantly exceeded the combination of olmesartan medoxomil and hydrochlorothiazide (40 mg and 25 mg, respectively) in reducing systolic Blood pressure on the background of moderate to severe arterial hypertension.
Similar results were observed in all patient subgroups, regardless of age, gender, or race.
The combination of active ingredients Edarbi Clo lowered blood pressure more effectively than the combined use of olmesartan medoxomil / hydrochlorothiazide in every hour of the 24-hour period between doses of drugs according to 24-hour blood pressure monitoring (ABPM).
Pharmacokinetics
After oral administration of Edarbi Clo in the blood plasma, the maximum concentration (C max) of azilsartan is determined within approximately 3 hours, the half-life (T½) is approximately 12 hours. Pharmacokinetic parameters of azilsartan, such as C max, the period of reaching C max (T Cmax) and the area under the "concentration-time curve" (AUC), when monotherapy is carried out with a drug and when it is combined with chlorthalidone are similar.
The volume of distribution (V d) of azilsartan is on average 16 liters, the connection with blood plasma proteins (mainly albumin) reaches more than 99%.
In the process of biotransformation of azilsartan, two primary metabolites are formed, mainly in the liver. The main metabolite (M-II) in the blood plasma is formed by O-dealkylation, the minor metabolite (M-I) - by decarboxylation. In humans, the AUC for these metabolites is 50% and less than 1%, respectively, compared with azilsartan. The metabolism of the latter is provided by the isoenzyme CYP2C9.
Azilsartan and its metabolites are excreted by the kidneys and through the intestines, after oral administration, about 55% of the drug (mostly in the form of the M-I metabolite) is detected in the feces and about 42% (in the form of the main substance - 15%, in the form of the M-II metabolite - 19%) - in urine. There were no significant differences in the pharmacokinetics of azilsartan in patients of different age and gender. There is no need to adjust the dose according to race.
Chlorthalidone after oral administration is absorbed from the gastrointestinal tract by 60%, on average, C max in blood plasma is reached within 12 hours, T½ is 40-50 hours. The AUC value of chlorthalidone is similar both when taken together with azilsartan medoxomil and when monotherapy is carried out, however, C max with combined use is 47% higher.
The bioavailability of Edarbi Clos when taken with food is not clinically significant.
In whole blood, chlorthalidone is mainly associated with carbonic anhydrase of erythrocytes. In blood plasma, about 75% of the substance is associated with its proteins, while 58% - with albumin. Chlorthalidone is excreted mostly unchanged. Data on comparative amounts of a substance excreted unchanged and in the form of metabolites are not provided.
Since chlorthalidone is a thiazide-like diuretic, it passes into breast milk. There is no information on the differences in the pharmacokinetic parameters of this substance in patients of different sexes, as well as depending on race. Chlorthalidone is excreted more slowly in elderly patients than in young patients, but this decrease is not clinically significant. In the presence of renal failure, accumulation of chlorthalidone may occur.
Indications for use
According to the instructions, Edarbi Clo is recommended for the treatment of essential hypertension in patients for whom combination treatment is indicated.
Contraindications
Absolute:
- severe diabetes mellitus;
- refractory form of hypokalemia;
- severe functional disorders of the liver (over 9 points on the Child-Pugh scale);
- anuria;
- renal failure, severe [with creatinine clearance (CC) below 30 ml / min];
- age up to 18 years;
- pregnancy and lactation;
- combined intake of aliskiren and aliskiren-containing agents in patients with diabetes mellitus or moderate / severe renal impairment [with a glomerular filtration rate (GFR) less than 60 ml / min / 1.73 m²];
- hypersensitivity to any of the constituents of the antihypertensive agent.
Relative (Edarbi Clos should be taken with caution):
- cerebrovascular ischemic lesions;
- ischemic cardiomyopathy;
- severe chronic heart failure (CHF) (NYHA functional class IV; due to lack of clinical experience of use);
- hypertrophic obstructive cardiomyopathy (GOKMP);
- mitral and aortic valve stenosis;
- mild / moderate degree of functional impairment of the liver (5-9 points on the Child-Pugh scale);
- impaired renal function (CC above 30 ml / min);
- stenosis of an artery of a single functioning kidney, bilateral stenosis of the renal arteries;
- condition after kidney transplantation (due to the lack of data on the use);
- hypokalemia;
- hyperuricemia, gout;
- primary hyperaldosteronism;
- systemic lupus erythematosus;
- bronchial asthma;
- conditions leading to a decrease in circulating blood volume (BCC), including diarrhea, vomiting, the use of high doses of diuretics, as well as adherence to a diet with limited table salt;
- age over 75 years.
Instructions for the use of Edarbi Clos: method and dosage
Edarbi Clo is taken orally once a day, regardless of food intake.
At the beginning of treatment, Edarbi Clo 40 + 12.5 mg is usually prescribed once a day.
If it is not possible to achieve adequate control of blood pressure, the dose of the drug can be increased to the maximum possible - 40 mg azilsartan medoxomil + 25 mg chlorthalidone 1 time per day.
Edarbi Cloe is required to be taken every day, without interruption. When discontinuing therapy, you should consult your doctor. If the next dose is missed, the next one must be taken at the usual time, you cannot double the dose.
With a sharp cancellation of azilsartan medoxomil after a long course of treatment (within six months), the development of the withdrawal syndrome was not observed. At the same time, at the end of long-term therapy, the abolition of Edarbi Clos is recommended, if possible, gradually.
Side effects
Side effects recorded against the background of the combined use of azilsartan medoxomil and chlorthalidone:
- CVS: often - a significant decrease in blood pressure;
- hematopoietic system: infrequently - anemia;
- digestive system: often - nausea, diarrhea; infrequently - vomiting;
- nervous system: often - dizziness, postural dizziness; infrequently - paresthesia, fainting (syncope);
- skin and subcutaneous tissues: infrequently - itching, skin rash;
- musculoskeletal system: infrequently - muscle spasms;
- allergic reactions: rarely - angioedema;
- laboratory indicators: very often - an increase in creatinine levels (reversible after the end of the intake); often - an increase in the concentration of urea (depending on the dose of chlorthalidone), an increase in glucose;
- metabolism: often - hyperuricemia; infrequently - increased concentration of potassium, hypokalemia, exacerbation of gout, hyponatremia;
- general reactions: often - peripheral edema, increased fatigue.
Side effects noted with the use of chlorthalidone in monotherapy:
- CVS: often - a significant decrease in blood pressure; rarely - arrhythmia;
- hematopoietic system: rarely - agranulocytosis, leukopenia, eosinophilia, thrombocytopenia;
- digestive system: often - gastrointestinal upset, loss of appetite; rarely, abdominal pain, constipation, jaundice, or intrahepatic cholestasis; extremely rare - pancreatitis;
- nervous system: rarely - headache;
- allergic reactions: often - urticaria;
- skin and subcutaneous tissues: rarely - cutaneous vasculitis, photosensitivity;
- respiratory system: rarely - allergic pulmonary edema;
- urinary system: rarely - allergic interstitial nephritis;
- metabolism: very often - hypokalemia, hyperlipidemia; often - hypomagnesemia; rarely - decompensation of concomitant diabetes mellitus, glucosuria, hypercalcemia; extremely rare - hypochloremic alkalosis;
- others: often - weakening of potency.
Side effects recorded during monotherapy with azilsartan medoxomil:
- CVS: infrequently - a marked decrease in blood pressure;
- digestive system: often - diarrhea; infrequently - nausea;
- nervous system: often - dizziness; infrequently - headache;
- allergic reactions: rarely - angioedema;
- skin and subcutaneous tissues: infrequently - itching, skin rash;
- musculoskeletal system: infrequently - muscle spasms;
- laboratory indicators: often - increased activity of creatine phosphokinase (CPK); infrequently - hyperuricemia, an increase in creatinine levels;
- general reactions: infrequently - peripheral edema, increased fatigue.
Overdose
When taking azilsartan medoxomil as a monotherapy drug in daily doses up to 320 mg for 7 days, its good tolerance was noted. Overdose symptoms can be dizziness and a pronounced decrease in blood pressure; in this condition, it is necessary to transfer the patient to the supine position, raising his legs. Also, measures are recommended to increase the BCC and conduct symptomatic therapy. The drug is not removed by dialysis.
When monotherapy with chlorthalidone, overdose symptoms include disturbances in water and electrolyte balance, dizziness, weakness, nausea. If there is a significant decrease in blood pressure, it is recommended to flush the stomach, and infusion (to normalize the water-electrolyte balance) and symptomatic therapy are also prescribed.
special instructions
In patients with hyponatremia and / or with reduced BCC during treatment with Edarbi Clos, there is a threat of clinically significant arterial hypotension. Before starting therapy, it is required to adequately correct hypovolemia by replacing the loss of electrolytes and fluid. Transient arterial hypotension is not a contraindication for further administration of the drug; after stabilization of blood pressure, treatment can be continued.
If, during therapy, there is a progressive deterioration in renal function (an increase in the level of urea nitrogen in the blood), it is recommended to temporarily stop or completely stop taking diuretics.
In patients with ischemic cerebral circulation disorders or ischemic cardiomyopathy, a sharp decrease in blood pressure can provoke the development of a stroke or myocardial infarction.
In patients whose renal activity and vascular tone are mainly dependent on the activity of the RAAS, for example, in the presence of severe CHF (IV FC according to the NYHA classification), severe renal failure or renal artery stenosis, therapy with drugs affecting the RAAS (ARA II and ACE inhibitors), may be associated with the appearance of acute arterial hypotension, oliguria, azotemia and, in rare cases, acute renal failure. The development of such complications cannot be excluded when using Edarbi Clos.
In patients with primary hyperaldosteronism, there is, as a rule, resistance to treatment with antihypertensive drugs that have a depressing effect on the RAAS. As a result, such patients are not recommended to take the drug.
Against the background of treatment with chlorthalidone, there is a possibility of developing hypokalemia, for this reason, it is necessary to regularly monitor the level of potassium in the blood. The onset of hypokalemia in patients receiving cardiac glycosides can lead to arrhythmias.
Influence on the ability to drive vehicles and complex mechanisms
Patients driving vehicles and / or complex mechanisms during the period of using Edarbi Clos need to be careful due to the possible appearance of excessive fatigue and dizziness.
Application during pregnancy and lactation
Taking Edarbi Clos during pregnancy and lactation is contraindicated. There are no data on the use of the drug by pregnant women.
Newborns whose mothers took azilsartan medoxomil need careful medical supervision, since they have an increased risk of developing arterial hypotension.
Chlorthalidone can enter the umbilical cord blood through the placental barrier and lead to the development of jaundice of the fetus or newborn, thrombocytopenia and other undesirable effects noted in adults.
If pregnancy is confirmed during therapy, the use of Edarbi Clo must be urgently discontinued and, if necessary, replaced with another drug approved for use in pregnant women.
It is not known whether azilsartan and / or its metabolites penetrate into human milk, but in animal studies, the ability of azilsartan and its metabolite M-II to penetrate into the milk of lactating rats was revealed. It has been established that chlorthalidone is excreted in breast milk.
If taking the drug is necessary during lactation, you need to stop breastfeeding. During this period, it is desirable to use drugs that have a proven safety profile.
Pediatric use
Edarbi Clos is prohibited from admission in patients under 18 years of age, since there is no information confirming the effectiveness and safety of its use in children and adolescents.
With impaired renal function
In patients with severe renal insufficiency (CC below 30 ml / min), Edarbi Klaue is contraindicated, since this category of patients does not have clinical experience of its use.
With mild and moderate renal impairment (CC above 30 ml / min), changes in the dosage regimen are not required, but it is recommended to regularly monitor blood pressure, potassium content and serum creatinine concentration.
For violations of liver function
The drug is contraindicated for use in the presence of severe functional disorders of the liver (over 9 points on the Child-Pugh scale) due to lack of experience in use. Patients with mild and moderate liver dysfunctions (5-9 points on the Child-Pugh scale) should use Edarbi Clos with caution, since even with small violations of water and electrolyte balance while taking diuretics, the risk of hepatic coma increases. It is required to carefully monitor the condition of patients in this risk group.
Use in the elderly
Elderly patients (over 65 years old) do not need to adjust the initial dose of Edarbi Clos. Persons over the age of 75 should use an antihypertensive agent with caution.
Drug interactions
- lithium preparations - the serum concentration of lithium in the blood reversibly increases and toxicity is manifested when taken simultaneously with ARA II (this combination is not recommended; if combined use is necessary, the lithium level should be regularly monitored);
- non-steroidal anti-inflammatory drugs (NSAIDs) - in patients with impaired renal function, elderly patients or with reduced BCC (including those taking diuretics), renal function may deteriorate, including the development of acute renal failure (at the beginning of the course, patients in this group risk, it is recommended to regularly monitor kidney function and drink enough fluid);
- selective inhibitors of COX-2 (cyclooxygenase-2), acetylsalicylic acid (in daily doses of more than 3 g) and non-selective NSAIDs - the antihypertensive effect is weakened;
- ARA II, ACE inhibitors - the threat of hyperkalemia, arterial hypotension and functional disorders of the kidneys (including acute renal failure) caused by double blockade of the RAAS increases;
- cardiac glycosides - due to the influence of a diuretic, the effects of hypokalemia are aggravated, including heart rhythm disturbances.
Possible interaction of azilsartan medoxomil with other drugs / substances:
- enzyme carboxymethylene butenolidase (in the liver and intestine) - the transformation of azilsartan medoxomil into azilsartan (active metabolite) occurs under the action of this enzyme during absorption from the gastrointestinal tract; according to in vitro studies, interactions based on inhibition of enzymes are unlikely;
- antacids (magnesium and aluminum hydroxide), amlodipine, digoxin, chlorthalidone, glibenclamide, fluconazole, metformin, ketoconazole, warfarin - no pharmacokinetic interaction was observed.
Possible interactions of chlorthalidone with other drugs / substances:
- allopurinol - the frequency of hypersensitivity reactions to this drug increases;
- amantadine - the threat of the development of undesirable effects caused by it is aggravated;
- anticholinergic drugs (biperiden, atropine) - the bioavailability of chlorthalidone increases due to a decrease in gastrointestinal motility and evacuation of stomach contents;
- MAO inhibitors, curariform muscle relaxants, antihypertensive drugs (methyldopa, guanethidine, slow calcium channel blockers, vasodilators, beta-blockers) - the effect of these drugs is enhanced;
- amphotericin, corticosteroids, adrenocorticotropic hormone (ACTH), carbenoxolone, beta 2- blockers - the hypokalemic effect of chlorthalidone is enhanced (it is required to control the level of potassium in the serum);
- antidiabetic oral agents and insulin - dose adjustments may be necessary;
- cholestyramine - the absorption of chlorthalidone is impaired and its pharmacological effect decreases;
- cyclophosphamide and methotrexate - it is possible to enhance the pharmacological effect of these drugs;
- cyclosporine - the risk of hyperuricemia and gout may be aggravated;
- vitamin D, calcium salts - the pharmacological effects of these drugs may increase to clinically significant.
Analogs
There is no information about the analogues of Edarbi Klaw.
Terms and conditions of storage
Store in its original packaging in a place protected from light and moisture, out of the reach of children, at a temperature not exceeding 25 ° C.
The shelf life is 3 years.
Terms of dispensing from pharmacies
Dispensed by prescription.
Reviews about Edarby Clos
According to reviews, Edarbi Clo is an effective drug used to treat essential hypertension. Patients also note a convenient dosage regimen of the drug and its diuretic effect, which helps to relieve edema.
In some reviews, they indicate the development of adverse reactions, such as severe weakness, vomiting, nausea. Many patients consider the disadvantages of Edarbi Clos too high, in their opinion, the cost of the drug.
Price for Edarby Clos in pharmacies
Approximate prices for Edarbi Clo (for a pack containing 28 tablets):
- Edarbi Clo 40 + 12.5 mg: 580–590 rubles;
- Edarbi Clo 40 + 25 mg: 630–720 rubles.
Edarby Clos: prices in online pharmacies
|
Drug name Price Pharmacy |
|
Edarbi Clo 40 mg + 12.5 mg film-coated tablets 28 pcs. 664 RUB Buy |
|
Edarbi Clo 40 mg + 25 mg film-coated tablets 28 pcs. 713 RUB Buy |
|
Edarbi Clo pills p.p. 40mg + 12.5mg 28 pcs 730 RUB Buy |
|
Edarbi Clo pills p.p. 40mg + 25mg 28 pcs RUB 785 Buy |
|
Edarbi Clo 40 mg + 25 mg tablets 98 pcs. 2047 RUB Buy |
|
Edarbi Clo 40 mg + 12.5 mg tablets 98 pcs. RUB 2091 Buy |
|
Edarby clos tab. p / o captivity. 40mg + 12.5mg No. 98 2348 RUB Buy |
|
Edarbi Clo pills p.p. 40mg + 25mg 98 pcs. 2429 RUB Buy |
| See all offers from pharmacies |
Anna Kozlova Medical journalist About the author
Education: Rostov State Medical University, specialty "General Medicine".
Information about the drug is generalized, provided for informational purposes only and does not replace the official instructions. Self-medication is hazardous to health!